Mentioned On
Episode Mentions
Pharma and BioTech Daily · May 13, 2026
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
“Phase 2 trial showed INBRX106 with Pembrolizumab doubled response rates in head and neck squamous cell carcinoma”
FDA Leadership Transition and Regulatory StrategyPrecision Oncology and Targeted Breast Cancer TherapiesBiosimilar Competition and Market Erosion
View Analysis